SML2682

RIPGBM

≥98% (HPLC)

• Sinónimos: N-(3-(Benzylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-N-(4-fluorobenzyl)acetamide, N-[1,4-Dihydro-1,4-dioxo-3-[(phenylmethyl)amino]-2-naphthalenyl]-N-[(4-fluorophenyl)methyl]acetamide, cRIPGBM precursor
• Fórmula empírica (notación de Hill): C₂₆H₂₁FN₂O₃
• Número CAS: 355406-76-7
• Peso molecular: 428.45
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Propiedades

• assay: ≥98% (HPLC)
• form: powder
• color: faint brown to very dark brown-red
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: O=C1C(N(CC2=CC=C(F)C=C2)C(C)=O)=C(NCC3=CC=CC=C3)C(C4=C1C=CC=C4)=O
• InChI: 1S/C26H21FN2O3/c1-17(30)29(16-19-11-13-20(27)14-12-19)24-23(28-15-18-7-3-2-4-8-18)25(31)21-9-5-6-10-22(21)26(24)32/h2-14,28H,15-16H2,1H3
• InChI key: COATXBHZYVUJQP-UHFFFAOYSA-N

Descripción

Biochem/physiol Actions

Orally active, brain-penetrant, GBM CSCs-selective apoptosis inducer with efficacy in a murine orthotopic xenograft model of glioblastoma multiforme in vivo.

RIPGBM is a brain-penetrant, orally available, glioblastoma multiforme (GBM) cancer stem cells (CSCs)-selective apoptosis inducer (GBM-1/-5/-39 EC50 = 220/290/890 nM; human neural progenitor cells (NPCs)/astrocytes/lung fibroblasts EC50 = 1.7/2.8/3.5 μM) with in vivo efficacy against intracranial human GBM orthotopic xenograft tumor growth in mice (50 mg/kg bid. po.). RIPGBM undergoes a cell type-selective metabolic redox conversion to preferentially form in GBM CSCs the derivative cRIPGBM that binds receptor-interacting protein kinase 2 (RIPK2, RIP2) and promotes the formation of a proapoptotic RIPK2/caspase-1 complex.

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• WGK: WGK 3
• Punto de inflamación (°F): Not applicable
• Punto de inflamación (°C): Not applicable